CNBC's Jim Cramer breaks down why he's keeping an eye on shares of Bristol Myers. Irv Gotti, Music Producer and Murder Inc.

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks. In this ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ... here that has to come out no matter what.” The CNBC host also shared his experience using DeepSeek ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older therapies, writes Julie Coleman for CNBC..Bristol ...

But Alzheimer's is the "really large market here," Bristol Myers Squibb CFO David Elkins told CNBC on Tuesday at the JPMorgan Health Care Conference in San Francisco. There are nearly 6 million ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC's Squawk ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...